Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Dalle Carbonare, Luca ^a   Frigo, Anna ^a   Francia, Giuseppe ^a   Davì, Maria Vittoria ^a   Donatelli, Luca ^a   Stranieri, Chiara ^a   Brazzarola, Paolo ^b   Zatelli, Maria Chiara ^c   Menestrina, Fabio ^b   Valenti, Maria Teresa ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; ARTICLE; BRAF GENE; CALCIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA EXTRACTION; RUNX2 GENE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD CELLS; CALCINOSIS; CASE-CONTROL STUDIES; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863601158     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2624     Document Type: Article

References (54)

1. Johannessen JV, Sobrinho-Simões M 1980 The origin and significance of thyroid psammoma bodies. Lab Invest 43:287-296
2. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ 2008 Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 23:361-372 (Pubitemid 351304666)
3. CohenMMJr 2009 Perspectives on RUNX genes: an update. Am J Med Genet Part A 149A:2629-2646
4. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T 1997 Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764 (Pubitemid 27516178)
5. Otto F, Lübbert M, Stock M 2003 Upstream and downstream targets of RUNX proteins. J Cell Biochem 89:9-18 (Pubitemid 36459094)
6. Shui C, Spelsberg TC, Riggs BL, Khosla S 2003 Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 18:213-221 (Pubitemid 36125913)
7. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER 2010 Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis 15:117-123
8. Endo T, Ohta K, Kobayashi T 2008 Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab 93:2409-2412 (Pubitemid 351831565)
9. Zhou H, Xu W, Qian H, Yin Q, Zhu W, Yan Y 2008 Circulating RNA as a novel tumor marker: an in vitro study of the origins and characteristics of extracellular RNA. Cancer Lett 259:50-60 (Pubitemid 350235091)
10. Ferracin M, Veronese A, Negrini M 2010 Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 10:297-308
11. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ 2010 Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251:499-505
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ 2009 Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58:1375-1381
13. Fleischhacker M, Schmidt B 2010 Free circulating nucleic acids in plasma and serum (CNAPS)-useful for the detection of lung cancer patients? Cancer Biomark 6:211-219
14. Thoma SJ, Lamping CP, Ziegler BL 1994 Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction. Blood 83:2103-2114 (Pubitemid 24112721)
15. Miura N, Shiota G, Nakagawa T, Miura N, Shiota G, Nakagawa T, Maeda Y, Sano A, Marumoto A, Kishimoto Y, Murawaki Y, Hasegawa J 2003 Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology 64:430-434 (Pubitemid 36682958)
16. Heid CA, Stevens J, Livak KJ, Williams PM 1996 Real time quantitative PCR. Genome Res 6:986-994 (Pubitemid 26388091)
17. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2[-ΔΔC(T)] method. Methods 25:402-408 (Pubitemid 34164012)
18. Valenti MT, Garbin U, Pasini A, Zanatta M, Stranieri C, Manfro S, Zucal C, Dalle Carbonare L 2011 Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARγ2 expression in MSCs-like of osteoporotic patients. PLoS One 6:e20363
19. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS 2005 Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102:1454-1459 (Pubitemid 40209191)
20. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M 2009 Positive association between nuclear Runx2 and oestrogen progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 45:2239-2248
21. Consorti F, Anello A, Benvenuti C, Boncompagni A, Giovannone G, Moles N, Scardella L, Antonaci A 2003 Clinical value of calcifications in thyroid carcinoma and multinodular goiter. Anticancer Res 23:3089-3092 (Pubitemid 36969866)
22. Seiberling KA, Dutra JC, Grant T, Bajramovic S 2004 Role of intrathyroidal calcifications detected on ultrasound as a marker of malignancy. Laryngoscope 114:1753-1757 (Pubitemid 39332249)
23. Triggiani V, Guastamacchia E, Licchelli B, Tafaro E 2008 Microcalcifications and psammoma bodies in thyroid tumors. Thyroid 18:1017-1018
24. Hatakeyama S, Gao YH, Ohara-Nemoto Y, Kataoka H, Satoh M 1997 Expression of bone morphogenetic proteins of human neoplastic epithelial cells. Biochem Mol Biol Int 42:497-505 (Pubitemid 28297653)
25. Hopkins DR, Keles S, Greenspan DS 2007 The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol 26:508-523 (Pubitemid 47575882)
26. Bai Y, Zhou G, Nakamura M, Ozaki T, Mori I, Taniguchi E, Miyauchi A, Ito Y, Kakudo K 2009 Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 22:887-894
27. Yamaguchi A, Komori T, Suda T 2000 Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and cbfa1. Endocr Rev 21:393-411 (Pubitemid 32275586)
28. Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235 (Pubitemid 36515285)
29. Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL 1999 Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J Bone Miner Res 14:1522-1535 (Pubitemid 29416678)
30. Merriman HL, van Wijnen AJ, Hiebert S, Bidwell JP, Fey E, Lian J, Stein J, Stein GS 1995 The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/PEBP2/runt domain transcription factor family: interactions with the osteocalcin gene promoter. Biochemistry 34:13125-13132
31. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS 2004 Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1-41 (Pubitemid 38581526)
32. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger MR, Esposito I, Löhr M, Friess H, Kleeff J 2007 Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 97:1106-1115 (Pubitemid 47587005)
33. Tonomoto Y, Tachibana M, Dhar DK, Onoda T, Hata K, Ohnuma H, Tanaka T, Nagasue N 2007 Differential expression of RUNX genes in human esophageal squamous cells carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology 73:346-356 (Pubitemid 351862027)
34. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC 2004 Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64:4506-4513 (Pubitemid 38856922)
35. Brubaker KD, Vessella RL, Brown LG, Corey E 2003 Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22 (Pubitemid 36613151)
36. Lim M, Zhong C, Yang S, Bell AM, Cohen MB, Roy-Burman P 2010 Runx2 regulates surviving expression in prostate cancer cells. Lab Invest 90:222-233
37. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K 2009 Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15:1032-1038
38. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M 1994 Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12:725-729 (Pubitemid 24110911)
39. Gerges N, Rak J, Jabado N 2010 New technologies for the detection of circulating tumour cells. Br Med Bull 94:49-64
40. Valenti MT, Dalle Carbonare L, Donatelli L, Bertoldo F, Zanatta M, Lo Cascio V 2008 Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells. Bone 43:1084-1092
41. Eszlinger M, Neumann S, Otto L, Paschke R 2002 Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. Eur J Endocrinol 147:575-582 (Pubitemid 35414554)
42. Wingo ST, Ringel MD,Anderson JS, Patel AD, Lukes YD, Djuh YY, Solomon B, Nicholson D, Balducci-Silano PL, Levine MA, Francis GL, Tuttle RM 1999 Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects. Clin Chem 45:785-789 (Pubitemid 29266607)
43. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T 1998 Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101:1296-1300 (Pubitemid 28166826)
44. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, Schlumberger M 1999 Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234 (Pubitemid 30646949)
45. Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA 2006 The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med 147:126-132 (Pubitemid 43288168)
46. Tsang JC, Lo YM 2007 Circulating nucleic acids in plasma/serum. Pathology 39:197-207 (Pubitemid 46439650)
47. ValentiMT,Dalle Carbonare L, Donatelli L, Bertoldo F, Giovanazzi B, Caliari F, Lo Cascio V 2009 STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett 273:122-126
48. Dalle Carbonare L, Gasparetto A, Donatelli L, Dellantonio A, Valenti MT 24 February 2011 Telomerase mRNA detection in serum of patients with prostate cancer. Urol Oncol Feb 24. 10.1016/j.urolonc.2010.12.017
49. Lo YM 2001 Circulating nucleic acids in plasma and serum: an overview. Ann NY Acad Sci 945:1-7 (Pubitemid 33022426)
50. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD, Godfrey TE 2004 Characterization of amplifiable, circulating RNAin plasma and its potential as a tool for cancer diagnostics. Clin Chem 50:564-573 (Pubitemid 38297307)
51. Lal A, Peters H, St. Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ 2001 Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343 (Pubitemid 32910575)
52. García JM, García V, Peña C, Domínguez G, Silva J, Diaz R, Espinosa P, Citores MJ, Collado M, Bonilla F 2008 Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 14:1424-1432 (Pubitemid 351872198)
53. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB 2008 Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3:e3694
54. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC 2009 BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration. biopsies. Eur J Endocrinol 161:467-473